Literature DB >> 25402950

The chaperone activity of clusterin is dependent on glycosylation and redox environment.

Philipp Rohne1, Hans Prochnow, Steven Wolf, Benjamin Renner, Claudia Koch-Brandt.   

Abstract

BACKGROUND/AIMS: Clusterin (CLU), also known as Apolipoprotein J (ApoJ) is a highly glycosylated extracellular chaperone. In humans it is expressed from a broad spectrum of tissues and related to a plethora of physiological and pathophysiological processes, such as Alzheimer's disease, atherosclerosis and cancer. In its dominant form it is expressed as a secretory protein (secreted CLU, sCLU). During its maturation, the sCLU-precursor is N-glycosylated and cleaved into an α- and a β-chain, which are connected by five symmetrical disulfide bonds. Recently, it has been demonstrated that besides the predominant sCLU, rare intracellular CLU forms are expressed in stressed cells. Since these forms do not enter or complete the secretory pathway, they are not proteolytically modified and show either no or only core glycosylation. Due to their sparsity, these intracellular forms are functionally poorly characterized. To evaluate the function(s) of these stress-related intracellular forms, we investigate for the first time the impact of proteolytic cleavage, differential glycosylation and the influence of the redox environment on the chaperone activity of CLU.
METHODS: Non-cleavable sCLU was generated by expression from a mutant construct of sCLU, in which the furin-like proprotein convertase (PC) recognition site was modified. After purification of recombinant uncleaved sCLU from the medium of over-expressing cells, we performed chaperone activity assays to compare the activities of wild-type (cleaved) and uncleaved mutant sCLU. Additionally, this approach enabled us to investigate the role of carbohydrates, the proteolytic maturation and reducing conditions on CLU chaperone activity. Further, we characterized the differentially treated CLU forms by using MALDI-TOF, CD-spectroscopy and Western blotting in addition to the functional assay.
RESULTS: We show that the PC-cleavage is dispensable for sCLU chaperone activity. Moreover, our data demonstrate that while fully deglycosylated sCLU lacks chaperone activity, partially deglycosylated sCLU is still capable of solubilizing target proteins. Most importantly, we here demonstrate for the first time that uncleaved sCLU is highly sensitive towards reducing conditions.
CONCLUSIONS: Our study provides evidence that unglycosylated intracellular CLU forms cannot exhibit a chaperone activity compared to sCLU. Additionally, we support recent postulates that glycosylated intracellular CLU forms may act as a redox sensor under oxidative stress conditions. Furthermore, we conclude that the proteolytic cleavage of sCLU is important to maintain full chaperone activity, i.e. in the presence of necrosis.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25402950     DOI: 10.1159/000366365

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  22 in total

1.  Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells.

Authors:  Jinmi Lee; Seok-Woo Hong; Hyemi Kwon; Se Eun Park; Eun-Jung Rhee; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Won-Young Lee
Journal:  Cell Stress Chaperones       Date:  2019-06-10       Impact factor: 3.667

2.  Exposure of vital cells to necrotic cell lysates induce the IRE1α branch of the unfolded protein response and cell proliferation.

Authors:  Philipp Rohne; Steven Wolf; Carolin Dörr; Julia Ringen; Andrew Holtz; René Gollan; Benjamin Renner; Hans Prochnow; Markus Baiersdörfer; Claudia Koch-Brandt
Journal:  Cell Stress Chaperones       Date:  2017-07-07       Impact factor: 3.667

3.  Novel insight into the role of clusterin on intraocular pressure regulation by modifying actin polymerization and extracellular matrix remodeling in the trabecular meshwork.

Authors:  Avinash Soundararajan; Ting Wang; Sachin A Ghag; Min H Kang; Padmanabhan P Pattabiraman
Journal:  J Cell Physiol       Date:  2022-05-14       Impact factor: 6.513

Review 4.  Clusterin, other extracellular chaperones, and eye disease.

Authors:  Mark R Wilson; Sandeep Satapathy; Shinwu Jeong; M Elizabeth Fini
Journal:  Prog Retin Eye Res       Date:  2021-12-10       Impact factor: 19.704

5.  Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Authors:  Celia M Torres-Arancivia; Deborah Chang; William E Hackett; Joseph Zaia; Lawreen H Connors
Journal:  Biochemistry       Date:  2020-11-03       Impact factor: 3.162

Review 6.  A Role for Clusterin in Exfoliation Syndrome and Exfoliation Glaucoma?

Authors:  Janey L Wiggs; Jae Hee Kang; BaoJian Fan; Hani Levkovitch-Verbin; Louis R Pasquale
Journal:  J Glaucoma       Date:  2018-07       Impact factor: 2.503

7.  Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer.

Authors:  Jian Wu; Hongqiang Qin; Ting Li; Kai Cheng; Jiaqiang Dong; Miaomiao Tian; Na Chai; Hao Guo; Jinjing Li; Xin You; Mingming Dong; Mingliang Ye; Yongzhan Nie; Hanfa Zou; Daiming Fan
Journal:  Oncotarget       Date:  2016-05-03

8.  Clusterin: full-length protein and one of its chains show opposing effects on cellular lipid accumulation.

Authors:  Suvarsha Rao Matukumalli; Ramakrishna Tangirala; C M Rao
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

9.  Single Nucleotide Polymorphism rs11136000 of CLU Gene (Clusterin, ApoJ) and the Risk of Late-Onset Alzheimer's Disease in a Central European Population.

Authors:  Vladimir J Balcar; Tomáš Zeman; Vladimír Janout; Jana Janoutová; Jan Lochman; Omar Šerý
Journal:  Neurochem Res       Date:  2020-11-18       Impact factor: 3.996

10.  Protective effect of clusterin on rod photoreceptor in rat model of retinitis pigmentosa.

Authors:  Andrew Vargas; Hwa Sun Kim; Erika Baral; Wan-Qing Yu; Cheryl Mae Craft; Eun-Jin Lee
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.